2014-10-01T09:40:10-05:00 2013-12-31 231406493 MORISON COGEN LLP 150 MONUMENT RD - SUITE 500 BALA CYNWYD PA 19004 990 2013-01-01 232818395 NATIONAL COMPREHENSIVE CANCER NETWORK NATI 2156900300 275 COMMERCE DRIVE NO 300 FORT WASHINGTON PA 19034 LISA KIMBRO CHIEF FINANCIAL OFFICER 2156900300 2014-09-24 1 JOSEPH M KISTNER CPA P00157086 2674403000 2013 2015-11-30 17:44:51Z ROBERT W CARLSON MD 275 COMMERCE DRIVE NO 300 FORT WASHINGTON PA 19034 22966968 0 X WWW.NCCN.ORG X 1993 DE OUR MISSION, AS AN ALLIANCE OF LEADING CANCER CENTERS DEVOTED TO PATIENT CARE, RESEARCH, AND EDUCATION IS TO IMPROVE THE QUALITY, EFFECTIVENESS, AND EFFICIENCY OF CANCER CARE SO THAT PATIENTS CAN LIVE BETTER LIVES. 23 23 98 1081 173763 0 14901085 14251457 7432102 7974208 114529 65795 605021 675508 23052737 22966968 2777128 2936757 0 0 10455790 10683431 0 0 462910 15425723 8761727 28658641 22381915 -5605904 585053 25197880 25948086 11126723 11366482 14071157 14581604 X OUR MISSION, AS AN ALLIANCE OF LEADING CANCER CENTERS DEVOTED TO PATIENT CARE, RESEARCH, AND EDUCATION IS TO IMPROVE THE QUALITY, EFFECTIVENESS, AND EFFICIENCY OF CANCER CARE SO THAT PATIENTS CAN LIVE BETTER LIVES. 0 1 9759459 7651424 WITH EXPERTS FROM MAJOR ACADEMIC CANCER CENTERS, DEVELOP AND UPDATE CLINICAL PRACTICE GUIDELINES FOR TREATMENT OF CANCER; INCLUDES FREE DISTRIBUTION OF CONTENT, AND EDUCATIONAL CONFERENCES AND SYMPOSIA TO COMMUNICATE CONTENT. 4142643 2936757 DEVELOPMENT OF A CLINICAL RESEARCH NETWORK OF PHYSICIANS AT MEMBER ACADEMIC CANCER CENTERS TO FACILITATE THE CONDUCT OF STUDIES TO ADVANCE THE STATE-OF-THE-ART IN CANCER CARE. 3481457 938292 DISSEMINATION OF PATIENT INFORMATION BASED ON GUIDELINES; DEVELOPMENT OF OTHER PUBLIC AND PROFESSIONAL INFORMATION PROGRAMS TO FACILITATE ACCESS TO CANCER SPECIALITY SERVICES; DEVELOPMENT AND DISSEMINATION OF MEASURES TO ASSESS THE QUALITY OF CARE. 1373826 60000 DEVELOP OUTCOMES OF CARE STUDIES TO ASSESS THE VIABILITY OF CANCER TREATMENT GUIDELINES TO MEASURE CLINICAL AND NON-CLINICAL OUTCOMES OF CARE DELIVERED UNDER NCCN GUIDELINES. 1373826 60000 18757385 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 230 0 1 98 1 1 1 0 0 0 0 0 0 0 0 0 X 23 23 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MS MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X LISA KIMBRO 2156900300 275 COMMERCE DRIVE SUITE 300 FORT WASHINGTON PA 19034 AL B BENSON III MD FACP DIRECTOR 2.00 X 0 0 0 DOUGLAS W BLAYNEY MD DIRECTOR 2.00 X 0 0 0 MARA G BLOOM JD MS DIRECTOR, SECRETARY 2.00 X 0 0 0 PETER R CARROLL MD MPH DIRECTOR 2.00 X 0 0 0 WILLIAM E CARSON III MD DIRECTOR 2.00 X 0 0 0 PETER F COCCIA MD DIRECTOR 2.00 X 0 0 0 THOMAS A D'AMICO MD DIRECTOR 2.00 X 0 0 0 TIMOTHY J EBERLEIN MD DIRECTOR, VICE CHAIR 2.00 X 0 0 0 PAUL F ENGSTROM MD FACP DIRECTOR 2.00 X 0 0 0 DAVID S ETTINGER MD FACP FCCP DIRECTOR 2.00 X 0 0 0 LARRY E KUN MD DIRECTOR 2.00 X 0 0 0 G DOUGLAS LETSON MD DIRECTOR 2.00 X 0 0 0 HARLAN LEVINE MD DIRECTOR 2.00 X 0 0 0 SCOTT M LIPPMAN MD DIRECTOR 2.00 X 0 0 0 RAY LYNCH CPA MBA DIRECTOR, TREASURER 2.00 X 0 0 0 MICHAEL N NEUSS MD DIRECTOR 2.00 X 0 0 0 DAVID G PFISTER MD DIRECTOR 2.00 X 0 0 0 SAMUEL M SILVER MD PHD DIRECTOR, CHAIR 2.00 X 0 0 0 F MARC STEWART MD DIRECTOR 2.00 X 0 0 0 DAN THEODORESCU MD PHD DIRECTOR 2.00 X 0 0 0 DONALD L TRUMP MD DIRECTOR 2.00 X 0 0 0 WILLIAM P VAUGHAN MD MBA DIRECTOR 2.00 X 0 0 0 RANDAL S WEBER MD DIRECTOR 2.00 X 0 0 0 ROBERT W CARLSON MD CHIEF EXECUTIVE OFFICER 40.00 X 477841 0 25699 PATRICIA J GOLDSMITH CHIEF OPERATING OFFICER 40.00 X 415886 0 45330 LISA G KIMBRO CHIEF FINANCIAL OFFICER 40.00 X 258498 0 56197 JOAN S MCCLURE SENIOR VP, CLINICAL INFORMATION & PUBLICATIONS 40.00 X 272804 0 49876 C LYN FITZGERALD VICE PRESIDENT, US & GLOBAL DEVELOPMENT 40.00 X 202758 0 63070 KRISTINA M GREGORY VICE PRESIDENT, CLINICAL INFORMATION OPERATIONS 40.00 X 191565 0 30610 DIANE E PAUL VICE PRESIDENT, ONCOLOGY RESEARCH PROGRAM 40.00 X 185719 0 42771 LAUREN GALLAGHER DIRECTOR DRUGS & BIOLOGICS PROGRAM 40.00 X 171175 0 53678 CHRISTINE MACCRACKEN SENIOR DIRECTOR BUSINESS INSIGHTS 40.00 X 169594 0 35093 WILLIAM T MCGIVNEY PHD FORMER CHIEF EXECUTIVE OFFICER 0.00 X 514410 0 28541 2860250 0 430865 22 1 1 0 THE WESTIN DIPLOMAT RESORT & SPA 3555 S OCEAN DRIVE HOLLYWOOD FL 33019 CONFERENCE PRODUCTION 1290326 BECKMAN RESEARCH INSTITUTE OF THE CITY O 1500 EAST DUARTE ROAD DUARTE CA 91010 DATA COLLECTION 590092 DANA-FARBER CANCER INSTITUTE 44 BINNEY STREET BOSTON MA 02115 DATA COLLECTION 513089 IBM CORPORATION 275 VIGER EAST MONTREAL, QUEBEC CA H2X 3R7 SOFTWARE CONSULTING 368325 DANA FARBERPARTNERS CANCER CENTER 450 BROOKLINE AVENUE BP320 BOSTON MA 02215 RESEARCH 359163 27 2342684 11908773 14251457 PERMISSION FEES 900099 2106871 2106871 LICENSE FEES 900099 1604784 1604784 GUIDELINE DISTRIBUTION 900099 1390990 1390990 SUBSCRIPTIONS 900099 1042415 1042415 EXHIBIT FEES 900099 603300 603300 1225848 1225848 7974208 65795 65795 501745 501745 ADVERTISING 541800 173763 173763 173763 22966968 8475953 173763 65795 2936757 2936757 1425029 1111083 280309 33637 6851434 5940589 603826 307019 422338 363034 41632 17672 1482007 1273911 146087 62009 502623 432047 49546 21030 249075 145300 103775 47400 12200 35200 1006995 962920 44075 41792 24908 16884 107502 53143 53561 798 1005246 734452 270759 35 897710 897710 747465 582619 149778 15068 2210135 2210135 204980 108566 96414 102504 653 101851 OUTCOMES DATABASE 475928 475928 PRINTING AND PUBLICATIO 411830 411830 HONORARIA 355300 355300 897865 622010 270213 5642 22381915 18757385 3161620 462910 3361681 4538577 15664500 15645978 1920122 2160685 3225137 2792655 94444 27777 277783 307431 4076325 3601342 654213 474983 25197880 25948086 2886568 2332675 8240155 9033807 11126723 11366482 X 7069141 9307820 7002016 5273784 14071157 14581604 25197880 25948086 585053 -74606 0 X X 0 1 X 1 0 X 17970391 22254488 16909721 14901085 14251457 86287142 17970391 22254488 16909721 14901085 14251457 86287142 27031295 59255847 181254 151856 460409 614667 567540 1975726 4980 62096 67076 7129446 2761376 8829913 7432102 7974208 34127045 122456989 0.48390 0.47990 X SCHEDULE A - PART II SECTION B LINE 10 OTHER INCOME INCLUDES THE FOLLOWING ITEMS: OUTCOMES DATABASE QUERIES $ 60,300 GUIDELINE DISTRIBUTION 1,390,990 PERMISSION FEES 2,106,871 SUBSCRIPTION REVENUE FROM THE NCCN COMPENDIA, CHEMOTHERAPY ORDER TEMPLATES AND FLASH UDPATES 1,042,415 LICENSE FEE REVENUE FOR LICENSING OF NCCN'S PRODUCTS 1,604,784 REGISTRATION FEES FOR NCCN EDUCATIONAL PROGRAMS 401,318 TRENDS SURVEY FEES FOR NCCN TRENDS REPORTS 134,500 TUITION FEES FOR NCCN ACADEMY 325,524 ACCESS FEES FOR NCCN CONTENT 60,000 EXHIBIT FEES FOR EXHIBITING AT NCCN EDUCATIONAL PROGRAMS 603,300 CONSULTING REVENUE 244,206 TOTAL $7,974,208 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 203735 28034 175701 1654871 1355589 299282 2217719 2217719 0 474983 X 22892362 -74606 -74606 22966968 0 22966968 22381915 0 22381915 0 22381915 PART X, LINE 2: NCCN FOLLOWS FASB ISSUED ACCOUNTING STANDARDS UPDATE NO. 2009-06, INCOME TAXES (TOPIC 740): IMPLEMENTATION GUIDANCE ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES AND DISCLOSURE AMENDMENTS FOR NONPUBLIC ENTITIES TAXES. FASB ASC 740 PRESCRIBES GUIDANCE FOR THE FINANCIAL STATEMENT RECOGNITION, MEASUREMENT AND DISCLOSURE OF UNCERTAIN TAX POSITIONS. TAX POSITIONS MUST MEET A MORE-LIKELY-THAN-NOT RECOGNITION THRESHOLD. THERE WERE NO TAX POSITIONS FOR WHICH IT IS REASONABLY POSSIBLE THAT THE TOTAL AMOUNTS OF UNRECOGNIZED TAX BENEFITS WILL SIGNIFICANTLY INCREASE OR DECREASE WITHIN THE NEXT YEAR. TAX YEARS FROM 2010 THROUGH 2013 REMAIN SUBJECT TO EXAMINATION BY MAJOR TAX JURISDICTIONS. EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES EDUCATIONAL PROGRAM 12366 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES EDUCATIONAL PROGRAM 982 0 0 0 0 0 0 13348 0 13348 0 0 0 0 0 0 SCHEDULE F - PART I LINE 3(F) THE METHOD USED TO ACCOUNT FOR THE ORGANIZATION'S EXPENDITURES IS THE ACCRUAL BASIS OF ACCOUNTING. THIS IS THE SAME METHOD USED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. 1 CITY OF HOPE COMPREHENSIVE CANCER CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 501(C)(3) 109645 RESEARCH DANA FARBER CANCER INSTITUTE 44 BINNEY STREET BP 320 BOSTON MA 02115 043320640 501(C)(3) 702125 RESEARCH DUKE UNIVERSITY 2200 W MAIN ST STE 810 DURHAM NC 27705 560532129 501(C)(3) 144084 RESEARCH FOX CHASE CANCER CENTER 640 COTTMAN AVENUE CHELTENHAM PA 19012 232003072 501(C)(3) 57950 RESEARCH GEORGIA CANCER SPECIALISTS 1835 SAVOY DRIVE SUITE 300 ATLANTA GA 30341 582181189 N/A 13424 RESEARCH RESEARCH HEALTH RESEARCH INC ROSWELL PARK CANCER CTR ELM AND CARLTON STREETS BUFFALO NY 14263 141402155 501(C)(3) 295592 RESEARCH JOHNS HOPKINS UNIVERSITY 733 BROADWAY STREET SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 193009 RESEARCH MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131624182 501(C)(3) 327385 RESEARCH NORTHWESTERN UNIVERSITY HEALTH SYSTEM 750 N LAKE SHORE DR CHICAGO IL 60611 362167817 501(C)(3) 92153 RESEARCH PPD DEVELOPMENT LLC 929 NORTH FRONT STREET WILMINGTON NC 28401 742325267 N/A 16515 RESEARCH STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 16210 RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1855 FOLSOM STREET ROOM 425 SAN FRANCISCO CA 94143 946036493 501(C)(3) 113290 RESEARCH THE UNIVERSITY OF TEXAS - MD ANDERSON CANCER CENTER 1515 HOLCOMBE AVENUE HOUSTON TX 772104390 746001118 501(C)(3) 189266 RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM COMPREHENSIVE CANCER CENTER 1824 6TH AVENUE SOUTH BIRMINGHAM AL 352943300 636005396 501(C)(3) 6863 RESEARCH UNIVERSITY OF MICHIGAN 3003 S STATE STREET ROOM 2044 ANN ARBOR MI 48104 386006309 501(C)(3) 112991 RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER DEPT OF FINANCE AT 40303 ATLANTA GA 311920303 620476822 501(C)(3) 78795 RESEARCH THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER 1960 KENNY ROAD COLUMBUS OH 43210 316401599 501(C)(3) 273649 RESEARCH UNIVERSITY OF WASHINGTON 825 EASTLAKE AVENUE SEATTLE WA 98109 916001537 115 108161 RESEARCH WASHINGTON UNIVERSITY 700 ROSEDALE AVENUE ST LOUIS MO 63112 430653611 501(C)(3) 81500 RESEARCH 16 3 PART I, LINE 2: NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) ENTERS INTO RESEARCH GRANT AGREEMENTS WITH INSTITUTIONS TO CONDUCT RESEARCH FOR INDIVIDUAL STUDY PROJECTS APPROVED BY NCCN'S SCIENTIFIC REVIEW COMMITTEES. THE SCOPE AND NATURE OF STUDIES TO BE PERFORMED BY GRANT RECIPIENTS ARE IN ACCORDANCE WITH THE APPROVED PROTOCOLS DEVELOPED BY THE PRINCIPAL INVESTIGATORS AND CONSISTENT WITH THE PROPOSALS SUBMITTED TO AND APPROVED BY THE NCCN SCIENTIFIC REVIEW COMMITTEES. PRINCIPAL INVESTIGATORS MUST SIGN A CERTIFICATION FORM WITH AN ATTESTATION THAT THEY WILL ABIDE BY THE TERMS OF THE NCCN RESEARCH AGREEMENT AT ISSUE AND THAT THEY HAVE NOT BEEN DISBARRED UNDER ANY RELEVANT STATUTES. IF AN INSTITUTION DOES NOT COMMENCE A STUDY WITHIN NINE MONTHS OF APPROVAL, NCCN TERMINATES THE STUDY IF A CORRECTIVE ACTION PLAN IS NOT SUBMITTED BY THE INVESTIGATOR AND APPROVED BY NCCN. FUNDING THAT HAD BEEN SUPPLIED BY NCCN TO AN INSTITUTION FOR A STUDY THAT DOES NOT COMMENCE WITHIN THE APPLICABLE SPECIFIED TIME PERIOD MUST BE RETURNED IMMEDIATELY TO NCCN BY THE INSTITUTION. DURING THE TERM OF THE GRANT, INSTITUTIONS REPORT TO NCCN ON A QUARTERLY BASIS THE STATUS AND PROGRESS OF THE FUNDED STUDIES. REPORTS INCLUDE AN ASSESSMENT OF TOTAL ENROLLMENT, ELIGIBILITY, AND ACCRUAL OF PATIENTS. IN CONSIDERATION FOR PERFORMANCE OF THE STUDY, NCCN DISTRIBUTES GRANT MONIES TO INSTITUTIONS WHEN CERTAIN BENCHMARKS FOR PATIENT ACCRUAL ARE MET AND THE FINAL PAYMENT IS DISBURSED UPON RECEIPT OF FINAL REPORTS AND / OR MANUSCRIPTS. INSTITUTIONS ARE REQUIRED TO RECONCILE STUDY EXPENSES AT TERMINATION OR COMPLETION AND RETURN UNUSED FUNDS TO NCCN WHICH ARE IN TURN RETURNED TO THE GRANTOR. X X X 1 0 0 0 0 0 0 0 0 ROBERT W CARLSON MD CHIEF EXECUTIVE OFFICER 477841 0 0 0 0 0 0 0 25699 0 503540 0 0 0 PATRICIA J GOLDSMITH CHIEF OPERATING OFFICER 415886 0 0 0 0 0 21975 0 23355 0 461216 0 0 0 LISA G KIMBRO CHIEF FINANCIAL OFFICER 258498 0 0 0 0 0 25500 0 30697 0 314695 0 0 0 JOAN S MCCLURE SENIOR VP, CLINICAL INFORMATION & PU 272804 0 0 0 0 0 25500 0 24376 0 322680 0 0 0 C LYN FITZGERALD VICE PRESIDENT, US & GLOBAL DEVELOPM 202758 0 0 0 0 0 20800 0 42270 0 265828 0 0 0 KRISTINA M GREGORY VICE PRESIDENT, CLINICAL INFORMATION 191565 0 0 0 0 0 19321 0 11289 0 222175 0 0 0 DIANE E PAUL VICE PRESIDENT, ONCOLOGY RESEARCH PR 185719 0 0 0 0 0 18936 0 23835 0 228490 0 0 0 LAUREN GALLAGHER DIRECTOR DRUGS & BIOLOGICS PROGRAM 171175 0 0 0 0 0 11500 0 42178 0 224853 0 0 0 CHRISTINE MACCRACKEN SENIOR DIRECTOR BUSINESS INSIGHTS 169594 0 0 0 0 0 11264 0 23829 0 204687 0 0 0 WILLIAM T MCGIVNEY PHD FORMER CHIEF EXECUTIVE OFFICER 514410 0 0 0 0 0 0 0 28541 0 542951 0 0 0 PART I, LINE 4A WILLIAM MCGIVNEY RECEIVED SEVERANCE OF $487,395. PATRICIA GOLDSMITH RECEIVED SEVERANCE OF $185,149 FORM 990, PART I, LINE 6, VOLUNTEERS: NCCN HAD 1,081 VOLUNTEERS COMMIT APPROXIMATELY 21,126 VOLUNTEER HOURS AS PANEL MEMBERS UPDATING EACH OF THE NCCN GUIDELINES FOR CANCER TREATMENT. FORM 990, PART III, LINE 3 NCCN PLACED ITS OUTCOMES DATABASE PROGRAM ON HIATUS DURING 2013 IN ORDER TO EVALUATE OPTIONS FOR A MORE EFFECTIVE AND EFFICIENT PROGRAM TO DEVELOP OUTCOMES OF CARE STUDIES TO ASSESS THE VIABILITY OF CANCER TREATMENT GUIDELINES TO MEASURE CLINICAL AND NON-CLINICAL OUTCOMES OF CARE DELIVERED UNDER NCCN GUIDELINES. FORM 990, PART VI, SECTION B, LINE 11 NCCN PROVIDES A DRAFT COPY OF THE FORM 990 TO THE FINANCE COMMITTEE OF THE BOARD OF DIRECTORS FOR ITS REVIEW AND APPROVAL PRIOR TO FILING THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C NCCN REQUIRES OFFICERS, DIRECTORS AND KEY EMPLOYEES TO ANNUALLY COMPLETE A CONFLICT OF INTEREST QUESTIONNAIRE. THIS QUESTIONNAIRE SHALL BE UPDATED AS NECESSARY TO REFLECT CHANGES DURING THE COURSE OF THE YEAR. COMPLETED QUESTIONNAIRES SHALL BE AVAILABLE FOR INSPECTION BY ANY BOARD MEMBER AND MAY BE REVIEWED BY NCCN'S LEGAL COUNSEL. SENIOR NCCN STAFF REVIEW THE CONFLICT OF INTEREST FORMS ANNUALLY, PROVIDE A REPORT TO THE EXECUTIVE COMMITTEE AND TAKE CORRECTIVE ACTION IF NEEDED. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF NCCN'S CHIEF EXECUTIVE OFFICER (CEO) DURING 2012 WAS REVIEWED BY AN EXECUTIVE SEARCH FIRM AND APPROVED BY NCCN'S EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. NCCN'S CHIEF EXECUTIVE OFFICER (CEO) POSITION WAS VACANT DURING MOST OF 2012. THE COMPENSATION OF NCCN'S CEO IS REVIEWED EVERY TWO TO THREE YEARS BY AN INDEPENDENT ORGANIZATION ENGAGED BY THE CHAIRMAN OF NCCN'S BOARD OF DIRECTORS TO CONDUCT A SALARY COMPARABILITY STUDY AND SURVEY. THE INFORMATION FROM THE SURVEY CONDUCTED BY THE INDEPENDENT ORGANIZATION IS FORWARDED TO NCCN'S EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS FOR THEIR REVIEW. EACH YEAR, THE EXECUTIVE COMMITTEE OF NCCN'S BOARD OF DIRECTORS RECEIVES INFORMATION REGARDING THE CEO'S PAST SALARY HISTORY AS WELL AS THE CEO'S ACCOMPLISHMENTS. NCCN'S EXECUTIVE COMMITTEE SCHEDULES A CONFERENCE CALL TO REVIEW THIS INFORMATION AND TO DISCUSS RECOMMENDATIONS FOR THE CEO'S SALARY AND BONUS FOR THE UPCOMING YEAR. FORM 990, PART VI, SECTION B, LINE 15B THE COMPENSATION OF NCCN'S CHIEF OPERATING OFFICER (COO) DURING 2013 WAS REVIEWED BY AN EXECUTIVE SEARCH FIRM. THE COMPENSATION OF NCCN'S CHIEF OPERATING OFFICER (COO), CHIEF FINANCIAL OFFICER (CFO), AND SENIOR VICE PRESIDENT OF CLINICAL INFORMATION AND PUBLICATIONS IS REVIEWED EVERY TWO TO THREE YEARS BY AN INDEPENDENT ORGANIZATION ENGAGED BY THE CEO OF NCCN. THE ORGANIZATION CONDUCTS A SALARY COMPARABILITY STUDY AND SURVEY FOR COMPARABLE POSITIONS IN SIMILAR ORGANIZATIONS. THE CEO REVIEWS THE SALARY STUDY AND SURVEY TO DETERMINE THE COMPENSATION FOR THE ABOVE KEY EMPLOYEES OF NCCN. FORM 990, PART VI, SECTION C, LINE 19 NCCN MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XII, LINE 2C: THE FINANCE COMMITTEE ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT AND SELECTION OF AN INDEPENDENT ACCOUNTANT. NCCN FOUNDATION 275 COMMERCE DRIVE STE 300 FORT WASHINGTON PA 19034 271536314 FOUNDATION DE 501(C)(3) LINE 7 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 NCCN FOUNDATION L 136101 FMV NCCN FOUNDATION O 530203 FMV NCCN FOUNDATION D 27778 FMV PART V LINE 2C SALARIES AND BENEFITS $455,644 PROFESSIONAL FEES 25,094 TRAVEL AND MEETINGS 45,344 OFFICE EXPENSE 898 SUPPLIES AND PRINTING 489 OTHER EXPENSES 404 INSURANCE 4 TELEPHONE 2,326 TOTAL $530,203